Research Peptide

Ageing starts at the cellular level, but scientists still don't have a single explanation for why cells change over time. Researchers study telomeres, telomerase, cellular senescence, DNA damage and other biological processes to understand what happens as cells age. That is where interest in the Epitalon research peptide comes in. Epitalon has attracted scientific attention because researchers have investigated its possible effects on telomere length and telomerase activity.

If you have been following peptide research in 2026, you have probably noticed one name coming up again and again: retatrutide. The interest is easy to understand. Researchers are no longer working with only early clinical data. Several Phase 3 trials have now reported results, and Eli Lilly says it plans to submit retatrutide to the U.S. FDA in the first quarter of 2027. At the same time, studies are looking beyond weight loss and into conditions such as type 2 diabetes, sle